EUFLEXXA®

EUFLEXXA® (Italian)

Manufacturer: Ferring Active Substance(s) : SODIUM…

ADD TO CART VIEW PRODUCT

-+

$209.00

About EUFLEXXA® and Its Manufacturer

EUFLEXXA® is a sterile, 1% sodium hyaluronate intra-articular viscosupplement designed to supplement depleted hyaluronic acid in osteoarthritic knee joints and restore the viscoelastic properties of synovial fluid [3][4]. In osteoarthritis, endogenous hyaluronic acid becomes reduced in concentration and depolymerized, compromising the lubricating and shock-absorbing function of synovial fluid [2]. EUFLEXXA® addresses this through local mechanical viscosupplementation rather than systemic pharmacologic action — it is not a corticosteroid and contains no steroidal compounds [3][4].

EUFLEXXA® is manufactured by Ferring Pharmaceuticals, a multinational life sciences company focused on biologics and specialty injectable therapies [4]. Within orthopedics, Ferring positions EUFLEXXA® as a non-avian HA viscosupplement for managing knee osteoarthritis symptoms, supported by evidence from controlled clinical trials, including the FLEXX trial and its open-label safety extension [1].

EUFLEXXA® Technology — Non-Avian HA and Molecular Profile

EUFLEXXA® is produced through bacterial fermentation, yielding a purified, non-avian sodium hyaluronate formulation [2][4]. This biofermentation process eliminates the avian protein exposure associated with rooster-comb-derived hyaluronic acid products — a clinically relevant distinction for patients with avian sensitivities and for practitioners managing formulary risk across a diverse patient population [2].

The molecular weight of EUFLEXXA® is approximately 2.4–3.6 million daltons, placing it in a mid-to-high viscosity range among intra-articular hyaluronic acid therapies [2]. This profile is intended to balance injectability with functional viscosity, supporting joint lubrication across movement cycles. EUFLEXXA® is a non-steroidal medical device; its mechanism of action is mechanical viscosupplementation, distinct from corticosteroid injections, which act through glucocorticoid receptor pathways [2][3]. EUFLEXXA®’s generic name is sodium hyaluronate.

EUFLEXXA® Product Spotlight

The EUFLEXXA® 20 mg/2 mL prefilled syringe is administered as a three-injection course. Each syringe delivers 20 mg of non-avian, biofermentation-derived sodium hyaluronate in 2 mL of solution as a sterile, single-use device for intra-articular knee injection [4].

The EUFLEXXA® dosage is 2 mL per injection, given once weekly for three consecutive weeks [1][4]. The three-injection regimen is designed to gradually restore synovial fluid properties across the course rather than delivering a single high-volume dose. Clinics managing scheduled viscosupplementation programs can buy EUFLEXXA® injection online through Medica Depot with verified LOT numbers and consistent supply.

Treatment Areas and Patient Indications

EUFLEXXA® is indicated for the relief of knee pain associated with osteoarthritis in patients who have not responded adequately to conservative therapy, including physical therapy, weight management, and simple analgesics [1][3]. It is FDA-approved for intra-articular knee injection; use in other joints is off-label and should be guided by clinical judgment and local regulations.

The non-avian biofermentation source makes EUFLEXXA® a practical consideration for patients with avian protein sensitivities who cannot tolerate rooster-comb-derived viscosupplements [2]. More broadly, EUFLEXXA® is suited to patients with moderate osteoarthritis seeking a non-surgical, non-corticosteroid approach to pain management, including those not yet ready for or not candidates for total knee arthroplasty.

In clinical workflows, EUFLEXXA® injections are commonly positioned within staged care pathways where viscosupplementation is used to extend conservative management before surgical intervention is considered.

Why Practitioners Choose EUFLEXXA®

EUFLEXXA®’s non-avian biofermentation source expands the eligible patient pool by removing avian protein exposure as a contraindication consideration [2]. For practices managing diverse patient demographics — including those with documented avian sensitivities — EUFLEXXA® offers a well-characterized alternative to rooster-comb-derived products, without requiring changes to injection protocols or billing workflows.

Furthermore, EUFLEXXA® is supported by a robust evidence base from controlled clinical trials. The randomized FLEXX trial demonstrated statistically significant improvements in pain and functional outcomes compared with placebo saline, with sustained benefits confirmed in the open-label safety extension [1]. This depth of evidence, combined with an established J code (J7323) and CPT billing pathway, reduces administrative friction for clinic billing teams managing high-volume viscosupplementation programs.

Administration and Injection Protocol

EUFLEXXA® is administered by a licensed healthcare professional as an intra-articular injection into the knee using aseptic technique [4]. Any significant joint effusion should be aspirated before injection to reduce intra-articular pressure and optimize distribution of the hyaluronan solution. The contents of a full 2 mL syringe are injected into the joint space once weekly for three consecutive weeks [1][4]. When both knees require treatment, a separate syringe is used for each joint. Repeat treatment courses are supported by open-label extension data confirming retreatment safety [1].

EUFLEXXA® is not a steroid. It is a hyaluronic acid medical device that acts via mechanical viscosupplementation rather than glucocorticoid receptor modulation [3][4]. Practitioners should follow the current product IFU for full administration guidance.

Onset of Effects and Copay Assistance Programs

Therapeutic response is typically gradual, reflecting the mechanical nature of viscosupplementation. Many patients notice improvement progressively over the weeks of the injection course, with benefit building after each dose [1][2]. Individual response varies based on osteoarthritis severity, patient weight, and activity level.

Regarding success rate: clinical trial data from the FLEXX study demonstrate statistically significant improvements in pain and function compared with placebo saline injections, though responses are variable and outcomes depend on individual patient factors [1].

Copay assistance programs may be available for eligible patients through Ferring Pharmaceuticals — practitioners should advise patients to confirm current program eligibility and terms directly with the manufacturer [4].

EUFLEXXA® vs Competing Viscosupplements

EUFLEXXA® vs ORTHOVISC®

Both EUFLEXXA® and ORTHOVISC® are non-avian sodium hyaluronate viscosupplements, making source material a neutral factor when comparing the two [2]. For practices that buy ORTHOVISC® alongside EUFLEXXA®, the more relevant differences are molecular weight profile, injection scheduling — three injections for EUFLEXXA® versus three to four for ORTHOVISC® — and formulary positioning.

EUFLEXXA® vs MONOVISC®

EUFLEXXA® and MONOVISC® are both non-avian hyaluronic acid viscosupplements but differ significantly in dosing: EUFLEXXA® is administered as three weekly injections, while MONOVISC® is a single-injection product [2]. Practices that buy MONOVISC® for single-visit convenience and stock EUFLEXXA® for staged protocols can offer patients a choice between course structures without switching HA source or billing pathway.

EUFLEXXA® vs HYALGAN®

EUFLEXXA® is non-avian and produced via bacterial fermentation, whereas HYALGAN® is an avian-derived sodium hyaluronate extracted from rooster comb sources [2]. HYALGAN® is typically administered over three to five injections and is generally considered a lower-molecular-weight formulation. The avian versus non-avian distinction is the most clinically significant difference here — practitioners who buy HYALGAN® or buy orthopedic injections at Medica Depot alongside EUFLEXXA® have both sourcing profiles available for patient-specific selection.

EUFLEXXA® vs SYNVISC®

EUFLEXXA® is a non-avian, biofermentation-derived sodium hyaluronate, while SYNVISC® is an avian-derived, chemically cross-linked hylan G-F 20 formulation with a different rheologic profile and molecular structure [2]. SYNVISC® is available as a multi-injection course or as SYNVISC-ONE® for single-injection administration. Both are available through Medica Depot — practitioners can buy SYNVISC® to compare cross-linked hylan G-F 20 against EUFLEXXA®’s biofermentation-derived sodium hyaluronate within the same procurement workflow.

EUFLEXXA® vs SUPARTZ®

EUFLEXXA® and SUPARTZ® are both sodium hyaluronate viscosupplements but differ in source and injection schedule: EUFLEXXA® is non-avian and given over three weekly injections, while SUPARTZ® is avian-derived and typically administered across five injections [2]. The difference in course length is typically the deciding factor for practices comparing the two — practitioners can buy SUPARTZ® at Medica Depot and evaluate both against their scheduling and coverage requirements.

EUFLEXXA® Safety Profile — Side Effects and Contraindications

Adverse events in clinical studies of EUFLEXXA® are primarily localized and transient [1]. Common injection-site reactions include pain or discomfort, swelling or effusion, and mild warmth or stiffness, most of which resolve without intervention within a few days [1][4]. Serious adverse events are rare; no clinically significant long-term safety concerns beyond typical transient reactions have been documented in the available clinical evidence [1].

Contraindications include hypersensitivity to hyaluronate or any EUFLEXXA® component, active joint infection, and skin disease or infection at the proposed injection site [3][4]. Practitioners should review the full contraindication and precaution information in the current product IFU before administering.

Regulatory Status and Billing

EUFLEXXA® is FDA-approved as a medical device under Premarket Approval (PMA P010029) for the relief of knee pain due to osteoarthritis in patients with inadequate response to conservative therapy [3]. Its mechanism is local mechanical viscosupplementation, distinguishing it from systemic pharmaceuticals and corticosteroids.

For billing, the EUFLEXXA® J code is J7323 — defined as hyaluronan or derivative, EUFLEXXA®, for intra-articular injection, per dose. The corresponding CPT code for the intra-articular injection procedure is 20610; practitioners should confirm the correct code combination and any payer-specific modifier requirements before submitting claims, as CMS coding is subject to periodic updates.

Medicare coverage may apply when coverage and documentation criteria are met, including documented knee osteoarthritis, failure of conservative therapy, and adherence to treatment frequency limits. Practices should review the current local coverage determination for documentation and interval requirements.

Medica Depot supplies EUFLEXXA® 20 mg/2 mL prefilled syringes at competitive wholesale prices for licensed practitioners, with group buy options, fast shipping, and verifiable LOT numbers to support consistent clinic inventory. Purchase EUFLEXXA® or buy EUFLEXXA® wholesale — add to cart or contact our team for volume pricing. Practices consolidating injectable procurement can also buy dermal fillers and buy HA dermal fillers through the same platform.

FAQs

What is EUFLEXXA®?

EUFLEXXA® is an FDA-approved, non-avian sodium hyaluronate viscosupplement supplied as a 20 mg/2 mL prefilled syringe for intra-articular treatment of knee pain due to osteoarthritis. It is administered as a three-injection weekly course [1][3].

What is EUFLEXXA® used for?

EUFLEXXA® is used to relieve knee pain associated with osteoarthritis in patients who have not responded adequately to conservative therapy such as physical therapy or oral analgesics [1][3].

Is EUFLEXXA® a steroid?

No. EUFLEXXA® is a hyaluronic acid medical device that works through mechanical viscosupplementation. It contains no corticosteroids or anti-inflammatory drugs [3][4].

What is EUFLEXXA®’s generic name?

The generic name for EUFLEXXA® is sodium hyaluronate, produced via bacterial fermentation as a non-avian source of hyaluronic acid [2][4].

How long does EUFLEXXA® take to work?

Improvement is typically gradual, with many patients noticing progressive relief over the course of the injection. Individual response varies based on osteoarthritis severity and patient factors [1][2].

What is the success rate of EUFLEXXA® injections?

Clinical trial data from the FLEXX study demonstrate statistically significant improvements in pain and function compared with placebo; however, response is variable and depends on individual patient factors including osteoarthritis severity and baseline function [1].

What are the long-term side effects of EUFLEXXA®?

No clinically significant long-term adverse effects are consistently documented beyond transient injection-site reactions. Serious adverse events are rare [1][4].

What is the CPT code for EUFLEXXA®?

The HCPCS J code for EUFLEXXA® is J7323 per dose; the injection procedure CPT code is 20610. Practitioners should verify current payer-specific requirements before submitting claims.

Is copay assistance available for EUFLEXXA®?

Copay assistance programs may be available through the manufacturer for eligible patients. Practitioners should advise patients to confirm current eligibility and program terms directly with Ferring Pharmaceuticals [4].

EUFLEXXA® vs ORTHOVISC® — what’s the difference?

Both are non-avian sodium hyaluronate viscosupplements. EUFLEXXA® is administered as a three-injection course; ORTHOVISC® is typically given over three to four injections. Differences center on the molecular weight profile and injection scheduling rather than on the source material [2].

Where can I order EUFLEXXA® at wholesale?

Licensed practitioners can order EUFLEXXA® at wholesale through Medica Depot, with competitive pricing, group buy options, fast shipping, and verifiable LOT numbers for clinic inventory management.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Seminars in Arthritis and Rheumatism. 2009. https://pubmed.ncbi.nlm.nih.gov/19539353/

[2] Bowman S, Awad ME, Hamrick MW, Hunter M, Fulzele S. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clinical and Translational Medicine. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5814393/

[3] U.S. Food and Drug Administration. Premarket Approval (PMA): EUFLEXXA (1% Sodium Hyaluronate) P010029. FDA. Last Updated 06/29/2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P010029

[4] Ferring Pharmaceuticals. EUFLEXXA (1% sodium hyaluronate) Prescribing Information. Ferring Pharmaceuticals. 2011. https://www.euflexxa.com/wp-content/uploads/2022/02/Euflexxa-PI.pdf